Revised. Amendments from Version 2
==================================

The text has been amended to make clearer that the evidence strongly suggests - but does not definitively prove - that ETS increases COPD risk.  Amendments have been made: (i) in the conclusions section of the abstract where we now say \"strongly suggests\" rather than \"suggests\", (ii) in the section \"Comparison with other recently published reviews\" in the Discussion, where the final paragraph now starts \"Generally these reviews point to an association between ETS exposure and risk of COPD without concluding that a causal relationship has clearly been established.  The present review confirms the association and provides evidence that is strongly suggestive of a true effect\".  It then ends with a sentence \"While this suggestion is not inconsistent with the view of the Global Burden of Disease Study 2017 (Reference added) that second-hand smoke is a risk factor for COPD, limitations of the evidence, discussed above, preclude a more definitive conclusion\"  which refers to a recent study mentioned by one of the reviewers. (iii) at the start of the Conclusions section after the Discussion which now begins \"Taken in conjunction with the strong association of smoking with COPD, the significant relationship seen for the main index of ETS exposure, and the evidence of a dose-response relationship is high;y suggestive that ETS also increases risk of COPD. However, the absence of\.....\" The two referees are now thanked in the Acknowledgement Section.

Introduction
============

This systematic review aims to present an up-to-date meta-analysis of available epidemiological evidence relating exposure to environmental tobacco smoke (ETS) from cigarettes to risk of chronic obstructive pulmonary disease (COPD) in lifelong non-smokers ("never smokers"). As described below, this review considers data from 28 longitudinal, case-control or cross-sectional studies ^[@ref-1]--\ [@ref-28]^.

It is long established that active smoking causes COPD, the U.S. Surgeon General concluding in 1964 ^[@ref-29]^ that "cigarette smoking is the most important of the causes of chronic bronchitis in the United States, and increases the risk of dying from chronic bronchitis". This opinion was echoed in their 2004 report ^[@ref-30]^, which felt the evidence "sufficient to infer a causal relationship between active smoking and chronic obstructive pulmonary disease morbidity and mortality", a view confirmed by a recent systematic review ^[@ref-31]^.

Sidestream smoke (released between puffs from the burning cone) contains similar chemicals to mainstream smoke (drawn and inhaled by smokers), but with different relative and absolute quantities of many individual constituents ^[@ref-32]^. However, sidestream smoke, after mixing with aged exhaled mainstream smoke, is diluted massively by room air before non-smokers inhale it. Smoke constituent levels in tissues of non-smokers are very much lower than in smokers, studies using cotinine typically indicating a relative exposure factor between 0.06% and 0.4% ^[@ref-33]--\ [@ref-35]^, with studies using particulate matter indicating a lower factor of 0.005% to 0.02% ^[@ref-36]--\ [@ref-44]^. Though an effect of ETS on COPD risk is plausible, it is difficult to establish this with certainty, as a threshold is a logical possibility. The same difficulty of establishing effects of ETS exposure on other diseases caused by smoking is also present, notably for lung cancer ^[@ref-31],\ [@ref-45]^.

In 2006, a review by the U.S. Surgeon General of the association of COPD with ETS exposure ^[@ref-46]^ concluded that "the evidence is suggestive but not sufficient to infer a causal relationship between second-hand smoke exposure and risk for COPD", the need for additional research also being highlighted. Although that review cited only nine of the 28 studies considered here ^[@ref-1],\ [@ref-3],\ [@ref-5]--\ [@ref-10],\ [@ref-13]^, and although various new studies have appeared since then, no other fully comprehensive review of this subject appears to have been undertaken.

This review, which is essentially an update of the 2006 review ^[@ref-46]^ is an attempt to assess the epidemiological evidence currently available, restricting attention to studies of COPD in which its relationship to one or more ETS exposure indices has been studied in never smokers. This restriction to never smokers is necessary as there is a very strong association of COPD with smoking ^[@ref-46]^, and it is difficult to reliably detect any ETS effect where a history of smoking is present. This is because the extent of a smoker's overall exposure to smoke constituents is determined largely by his own smoking habits and hardly at all by his much smaller ETS exposure, and also because smoking and ETS exposure are correlated (e.g. since smokers tend to marry smokers). Any errors in assessing smoking history are therefore likely to cause a residual confounding effect much larger than any plausible ETS effect ^[@ref-47]^.

As the 2006 US Surgeon General's Report ^[@ref-46]^ notes "COPD is a non-specific term, defined differently by clinicians, pathologists, and epidemiologists, each using different criteria based on symptoms, physiologic impairment, and pathologic abnormalities". That report goes on to state that "the hallmark of COPD is the slowing of expiratory airflow measured by spirometric testing, with a persistently low FEV ~1~ \[forced expiratory volume in one second\] and a low ratio of FEV ~1~ to FVC \[forced vital capacity\] despite treatment". International guidelines ^[@ref-48]^ define COPD as post-bronchodilator FEV ~1~/FVC \<0.70, with severity classified by subdividing FEV ~1~ as a percentage of predicted into four groups (≥80, \<80, \<50 and \<30%). The term COPD was little used until the 1980s, and diagnoses commonly used earlier (e.g. chronic bronchitis and emphysema) do not correspond exactly to what is now termed COPD. The studies we selected for review used disease definitions close enough to COPD as now defined to reasonably allow overall assessment. Some studies present additional results using criteria corresponding to severer forms of the disease. While these data are presented here, they are not included in our detailed meta-analyses.

Materials and methods
=====================

This systematic review was conducted according to PRISMA guidelines ^[@ref-49]^.

Study inclusion and exclusion criteria
--------------------------------------

Attention is restricted to epidemiological longitudinal, case-control or cross-sectional studies which provide risk estimates for never (or virtually never) smokers for any of the following indices of ETS exposure: spouse, partner, cohabitant, at home, at work, in adulthood, in childhood.

The term COPD is relatively recent, so we also included studies with outcomes described otherwise. Following the strategy used in our review of smoking and COPD ^[@ref-31]^, outcomes "could be based on International Classification of Diseases (ICD) codes, on lung function criteria, on a combination of lung function criteria and symptoms, or on combinations of diagnosed conditions....where diagnoses were extracted from medical records or reported in questionnaires". Acceptable combinations of diagnosed conditions had to include both chronic bronchitis and emphysema, but could also additionally include asthma, acute and unqualified bronchitis or bronchiectasis. However, studies were rejected where results were only available for emphysema, for chronic bronchitis, for respiratory symptoms such as cough or phlegm, or for lung function criteria not equating to COPD. Over-broad definitions such as respiratory disease were also not accepted. Acceptable lung function criteria included those of the Global Initiative for Chronic Obstructive Lung Disease (GOLD), the European Respiratory Society, and the British and American Thoracic Societies,

Studies which provide near equivalent definitions of "never smokers" are also accepted; thus never smokers can include occasional smokers or smokers with a minimal lifetime duration of smoking or number smoked. Risk estimates may be based on relative risks (RRs), hazard ratios (HRs), or odds ratios (ORs), and must either be provided directly or be capable of being estimated from the data provided.

Literature searches
-------------------

A PubMed search identified papers published up to June 2016 using the term "COPD AND (ENVIRONMENTAL TOBACCO SMOKE OR PASSIVE SMOKING OR SECONDHAND SMOKE EXPOSURE OR INVOLUNTARY SMOKING)", with restriction to humans. After rejecting papers that were clearly irrelevant based on the abstract, copies of the others were obtained for inspection. Other potentially relevant papers were obtained from reference lists in the 2006 Surgeon General report ^[@ref-46]^, an earlier review we conducted ^[@ref-47]^ and relevant review papers identified in the search. The complete list of potentially relevant papers were then looked at in detail to determine those which described studies satisfying the selection criteria, the rejected papers also including those where an alternative paper provided results from the same study that were more useful (e.g. based on a longer follow-up, a larger number of cases, or using a disease definition closer to COPD as currently defined).

Data recorded
-------------

Details were extracted from relevant publication on the following: study author; year of publication; study location; study design; sexes included; disease definition; number of cases; potential confounding variables considered; and never smoker definition. An effect estimate together with its associated 95% confidence interval (CI) was obtained, where available, for ETS exposure at home, at work, in adulthood, childhood, and from these sources combined. Choice between multiple definitions of COPD followed the rules of Forey *et al.* ^[@ref-31]^, except that here we also obtained additional estimates, if available, for severer COPD. We preferred effect estimates where the denominator was with no (or minimal) exposure to the ETS type considered rather than with no exposure to any ETS. Effect estimates and 95% CIs extracted were sex-specific, if possible, and for longitudinal studies were for the longest follow-up available. Estimates adjusted for covariates, where available, were generally preferred to unadjusted estimates, except that results adjusted for symptoms or precursors of COPD were not considered. Where a study provided multiple adjusted estimates, we used that adjusted for most covariates. Dose-response data were also extracted, where available.

Derivation of effect estimates
------------------------------

For a study reporting effect estimates and CIs only by exposure level, that for the overall unexposed/exposed comparison was estimated using the Morris and Gardner method ^[@ref-50]^ for unadjusted data or the Hamling *et al.* method ^[@ref-51]^ for adjusted data. These methods also allowed estimation of the significance of dose-related trends, if not given in the source publication.

Alternative types of effect estimates
-------------------------------------

As the great majority of effect estimates were ORs derived from case-control or cross-sectional studies, and as the RRs or HRs from longitudinal studies were all based on low incidences, where the OR would be virtually the same, all estimates were treated as if they were ORs. In the rest of this paper, we use OR rather than referring to specific types of effect estimate.

Meta-analyses
-------------

A pre-planned set of fixed-effect and random-effects meta-analyses were carried out using standard methods ^[@ref-52]^. Heterogeneity was quantified by H, the ratio of the heterogeneity chi squared to its degrees of freedom. The I-squared statistic ^[@ref-53]^ is related to H by the formula I ^2^ = 100 (H-1)/H. Publication bias tests were also conducted using the Egger method ^[@ref-54]^.

Our main analyses included OR estimates for the exposure most closely equivalent to "spouse ever smoked" where results were provided or could be estimated. This selection was based on the source of exposure (spouse highest preference, then partner, cohabitant, home or work). Spousal smoking is traditionally used for studying possible ETS effects, it being clearly demonstrated that women married to a smoker have much higher cotinine levels than women married to a non-smoker ^[@ref-55]^. Apart from the meta-analyses using all available estimates, meta-analyses also investigated variation in the OR according to a list of pre-defined factors, and using the following subsets: continent (North America, Asia, Europe, multicountry); publication period (1976--1990, 1991--2005, 2006--2016); study type (longitudinal, case-control, cross-sectional); sex (males, females, combined); diagnosis (mortality or hospitalisation, GOLD stage 1+, other); method of taking asthma into account (included as part of the COPD definition, adjusted for, asthmatic participants excluded, ignored); number of cases estimate based on (\<50, 50--149, 150+ cases); extent of confounder adjustment (unadjusted for age, adjusted for age and at most four other variables, adjusted for age and five or more variables); never smoker definition (never smoked any product, never smoked but product unstated, other -- including never cigarette smoker, occasional smoker or very short-term smoker); and definition of exposure index (spouse specifically, other exposure at home, other).

Meta-analyses were also carried out for the main index using the estimates for severer COPD, and also for other indices of exposure with sufficient data (workplace, overall adult -- including at least home and work, childhood). Here, data were too limited to study variation in the OR by the subsets described above.

Results of the overall meta-analyses are displayed as forest plots. In each plot, individual estimates are listed in increasing order of the OR. For the main index, estimates are grouped by region. Random-effects estimates are also shown. The estimates are not only shown numerically, but in graphical form on a logarithmic scale, where the OR is shown as a square, the area of which is proportional to its inverse-variance weight. Arrows warn when the CI goes outside the range of the plot.

Study quality and risk of bias
------------------------------

We did not attempt to derive any overall score based on study quality and risk of bias for each individual study, as the relative importance of different sources of bias or poor study quality is difficult or impossible to assess accurately. Instead, we attempted to gain insight into this in two ways. First, as mentioned in the previous section, we carried out meta-analyses showing how the OR varied by some relevant aspects linked to study quality and bias, such as study size, study type, source of diagnosis, method of taking asthma into account, and extent of confounder adjustment. Second, we considered factors affecting quality and bias in the discussion section, including some factors that affected all or virtually all of the studies.

Results
=======

Searches
--------

The PubMed search produced 509 hits. As summarized in [Figure 1](#f1){ref-type="fig"}, Seventy-five were considered of potential relevance based on the abstracts, 15 of which proved to meet the inclusion criteria on examination of the papers themselves. Further examination of reference lists in reviews ^[@ref-46],\ [@ref-47],\ [@ref-56]--\ [@ref-63]^ and in papers obtained identified a further 40 papers of potential relevance, 13 of which met the inclusion criteria. Of the 87 papers examined but not accepted, the most common reasons for rejection were no results for never smokers (38 papers), not COPD as defined (26), no control group or no results for unexposed participants (11) and better results for the same cohort given in another paper (9), some studies being rejected for more than one reason. Supplementary File 1 gives details of the studies rejected and fuller reasons for rejection.

![Flow-chart of study selection and exclusion criteria.\
The flow-chart shows the number of articles identified from the PubMed search and from reference lists of reviews and articles obtained, as well as showing those excluded, with reasons for exclusion. Note that some articles were excluded for multiple reasons.](f1000research-7-24188-g0000){#f1}

Studies identified
------------------

[Table 1](#T1){ref-type="table"} gives details of the 28 epidemiological studies that met the inclusion criteria, including author, reference(s), publication year, location, design, sexes included, disease definition, account taken of asthma, and numbers of cases in never smokers. The studies are listed in chronological order of publication and are given consecutive identifying study numbers.

###### Studies providing evidence on COPD and ETS exposure in never smokers.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study\   Author ^[a](#fn1){ref-type="other"}^   Year ^[b](#fn2){ref-type="other"}^   Location       Type ^[c](#fn3){ref-type="other"}^   Sexes\                            Age\                                  Definition of COPD used ^[e](#fn5){ref-type="other"}^                                Accounting\                               No. of\
  No.                                                                                                                                      included                          range ^[d](#fn4){ref-type="other"}^                                                                                        for asthma                                cases ^[f](#fn6){ref-type="other"}^
  -------- -------------------------------------- ------------------------------------ -------------- ------------------------------------ --------------------------------- ------------------------------------- ------------------------------------------------------------------------------------ ----------------------------------------- -------------------------------------
  1        Lebowitz ^[@ref-1]^                    1976                                 USA            CS                                   M,F                               15+                                   Asthma, bronchial trouble\                                                           Included                                  246
                                                                                                                                                                                                                   or emphysema (physician\                                                                                                       
                                                                                                                                                                                                                   diagnosis, questionnaire report)                                                                                               

  2        Comstock ^[@ref-2]^                    1981                                 USA            CS                                   M ^[g](#fn7){ref-type="other"}^   20+                                   FEV ~1~/FVC \<0.70 (spirometry test ^[h](#fn8){ref-type="other"}^)                   Ignored                                   30

  3        Hirayama ^[@ref-3]^                    1984                                 Japan          L15                                  F                                 40+                                   Emphysema or chronic\                                                                Ignored                                   130
                                                                                                                                                                                                                   bronchitis (mortality)                                                                                                         

  4        Krzyzanowski ^[@ref-4]^                1986                                 Poland         L13                                  M,F                               19--70                                FEV1 \<65% predicted\                                                                Ignored                                   37
                                                                                                                                                                                                                   (spirometry test ^[h](#fn8){ref-type="other"}^)                                                                                

  5        Lee ^[@ref-5]^                         1986                                 England        CC                                   M,F                               35--74                                Chronic bronchitis ^[i](#fn9){ref-type="other"}^\                                    Ignored                                   26
                                                                                                                                                                                                                   (hospitalisation)                                                                                                              

  6        Kalandidi ^[@ref-6]^                   1987                                 Greece         CC                                   F                                 40--79                                Chronic obstructive lung\                                                            Excluded ^[j](#fn10){ref-type="other"}^   103
                                                                                                                                                                                                                   disease (hospitalisation)                                                                                                      

  7        Sandler ^[@ref-7]^                     1989                                 USA            L12                                  M,F                               16+                                   Emphysema or bronchitis\                                                             Ignored                                   19
                                                                                                                                                                                                                   (mortality)                                                                                                                    

  8        Dayal ^[@ref-8]^                       1994                                 USA            CS ^[k](#fn11){ref-type="other"}^    M,F                               Adults                                Chronic bronchitis, emphysema\                                                       Included                                  219
                                                                                                                                                                                                                   or asthma (diagnosis,\                                                                                                         
                                                                                                                                                                                                                   questionnaire report)                                                                                                          

  9        Forastiere ^[@ref-9]^                  2000                                 Italy          CS ^[l](#fn12){ref-type="other"}^    F                                 25--74                                COPD (physician diagnosis,\                                                          Ignored                                   50
                                                                                                                                                                                                                   questionnaire report)                                                                                                          

  10       Enstrom ^[@ref-10]^                    2003                                 USA            L39                                  M,F                               31+                                   COPD (mortality)                                                                     Included                                  264

  11       De Marco ^[@ref-11]^                   2004                                 16 countries   CS                                   M,F                               20--44                                COPD (GOLD stage 1+) ^[h](#fn8){ref-type="other"}^                                   Ignored                                   156

  12       Celli ^[@ref-12]^                      2005                                 USA            CS                                   M,F                               30--80                                FEV ~1~/FVC \<0.70 (spirometry test ^[h](#fn8){ref-type="other"}^)                   Ignored                                   414 ^[m](#fn13){ref-type="other"}^

  13       McGhee ^[@ref-13]^                     2005                                 Hong Kong      CC                                   M,F                               60+                                   COPD (including pulmonary\                                                           Ignored                                   138
                                                                                                                                                                                                                   heart disease, mortality)                                                                                                      

  14       Sezer ^[@ref-14]^                      2006                                 Turkey         CC                                   F                                 38+                                   COPD (specialist clinic\                                                             Ignored                                   74
                                                                                                                                                                                                                   diagnosis)                                                                                                                     

  15       Xu ^[@ref-15]^                         2007                                 China          CC                                   M,F                               35+                                   COPD (hospital diagnosis\                                                            Ignored                                   1097
                                                                                                                                                                                                                   of emphysema or chronic\                                                                                                       
                                                                                                                                                                                                                   bronchitis, questionnaire report)                                                                                              

  16       Yin ^[@ref-16]^                        2007                                 China          CS                                   M,F                               51+                                   COPD (GOLD stage 1+ but\                                                             Excluded                                  429
                                                                                                                                                                                                                   without bronchodilator)                                                                                                        

  17       Zhou ^[@ref-17]^                       2009                                 China          CS                                   M,F                               40+                                   COPD (GOLD stage 1+) ^[n](#fn14){ref-type="other"},\ [o](#fn15){ref-type="other"}^   Ignored                                   644

  18       Wu ^[@ref-18]^                         2010                                 Taiwan         CC                                   F                                 40+                                   COPD (GOLD stage 1+)                                                                 Excluded                                  168

  19       Jordan ^[@ref-19]^                     2011                                 England        CS                                   M,F                               40+                                   COPD (GOLD stage 1+ but\                                                             Excluded                                  779 ^[m](#fn13){ref-type="other"}^
                                                                                                                                                                                                                   without bronchodilator) ^[p](#fn16){ref-type="other"}^                                                                         

  20       Lamprecht ^[@ref-20]^                  2011                                 14 countries   CS                                   M,F                               40+                                   COPD (GOLD stage 1+) ^[n](#fn14){ref-type="other"},\ [q](#fn17){ref-type="other"}^   Adjusted                                  523

  21       Chen ^[@ref-21]^                       2012                                 China          CS                                   M,F                               60+                                   COPD (physician diagnosis,\                                                          Ignored                                   149
                                                                                                                                                                                                                   questionnaire report)                                                                                                          

  22       He ^[@ref-22]^                         2012                                 China          L17                                  M,F                               51--87                                COPD (mortality or GOLD stage\                                                       Ignored                                   36
                                                                                                                                                                                                                   1+) ^[r](#fn18){ref-type="other"}^                                                                                             

  23       Waked ^[@ref-23]^                      2012                                 Lebanon        CS                                   M,F                               40+                                   COPD (GOLD stage 1+)                                                                 Ignored                                   25

  24       Moreira ^[@ref-24]^                    2013                                 Brazil         CS                                   F                                 40+                                   COPD (GOLD stage 1+)                                                                 Excluded                                  43

  25       Eze ^[@ref-25]^                        2014                                 Switzerland    CS                                   M,F                               18--65                                COPD (GOLD stage 1+) ^[h](#fn8){ref-type="other"}^                                   Ignored                                   444

  26       Hagstad ^[@ref-26]^                    2014                                 Sweden         CS                                   M,F                               20--77                                COPD (GOLD stage 1+)                                                                 Ignored                                   41 ^[m](#fn13){ref-type="other"}^

  27       Kim ^[@ref-27]^                        2014                                 Korea          CS                                   M,F                               40+                                   COPD (GOLD stage 1+ but\                                                             Adjusted                                  323
                                                                                                                                                                                                                   without bronchodilator)                                                                                                        

  28       Tan ^[@ref-28]^                        2015                                 Canada         CS                                   M,F                               40+                                   COPD (LLN, FEV1/FVC\                                                                 Adjusted                                  161
                                                                                                                                                                                                                   \<5th centile) ^[s](#fn19){ref-type="other"}^                                                                                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ First author and reference of principal publication

^b^ Year of publication

^c^ Study types are CC = case-control, CS = cross-sectional, L = longitudinal. For longitudinal studies, number of years follow-up is shown

^d^ Age at baseline for longitudinal studies

^e^ Definition of principal COPD outcome is shown. Definition of severer COPD used is shown in footnotes, along with alternative definitions for which results are available

^f^ Number of cases in lifelong non-smokers

^g^ Study also included females, but none had COPD

^h^ No mention of use of bronchodilator prior to spirometry

^i^ Named as chronic bronchitis, but defined by authors as ICD 9 ^th^ revision 491, 492, 496 so equates to COPD

^j^ Ignored for controls

^k^ Analysed as a nested CC study

^l^ Never smoking women had been identified by earlier studies in the same areas

^m^ Approximate estimate

^n^ Severer outcome definition based on GOLD Stage 2+

^o^ Alternative results are also available for GOLD stage 0+

^p^ Severer outcome definition based on NICE criteria (FEV ~1~/FVC \<0.7 and FEV ~1~ \<80% predicted) described as equivalent to GOLD stage 2+ (no bronchodilator, omitting participants with diagnosis of asthma). Alternative results are also available based on the LLN criteria, for "clinically significant COPD" based on the LLN, GOLD and NICE criteria, and including participants with diagnosis of asthma

^q^ Alternative results are also available using the LLN criteria

^r^ Based on death certificate, supplemented by medical records for lung function if their death was not from COPD

^s^ Severer outcome definition is based on LLN criteria plus FEV ~1~\<80% predicted

The included studies are mainly of representative populations, except that studies 18 and 26 have a large proportion with respiratory symptoms. Of the 28 studies, one was published in the 1970s, six in the 1980s, one in the 1990s, nine between 2000 and 2009 and 11 more recently.

Nine studies were conducted in Europe or the Middle East, subsequently referred to as "Europe" (two in England, and one each in Greece, Italy, Lebanon, Poland, Sweden, Switzerland and Turkey), while nine took place in Asia (five in China, and one each in Hong Kong, Japan, Korea and Taiwan), seven in North America (six in the USA and one in Canada) and one in South America (Brazil). Two studies presented combined results, one from 16 countries, the other from 14.

Five studies were longitudinal in design, with the length of follow-up varying from 12 to 39 years, one was a cross-sectional study analysed as a nested case-control study, 16 other studies were cross-sectional, with the remaining six of case-control design.

Most studies were of both sexes, though six studies considered only females.

Two studies considered those with a minimum age of 60, with a further 16 having a minimum age between 35 and 51. Other studies had a lower minimum age.

Definitions of outcome used varied by study. Seven studies required the case to have died or been hospitalised for COPD, while a further 12, mainly relatively recent cross-sectional studies, used COPD as defined by the GOLD stage 1+ criteria. The remaining nine studies used other definitions, as detailed in [Table 1](#T1){ref-type="table"}. Five studies (17, 19, 20, 26, 28) also provided results for severer COPD (generally equivalent to GOLD 2+, see footnotes to [Table 1](#T1){ref-type="table"}).

Twenty-one studies ignored asthma in their outcome definition and analysis, with the remaining 12 studies equally divided into those that included asthma in their outcome definition, excluded asthmatics, or adjusted for asthma status in analysis.

Most studies were small, with ten studies considering less than 100 cases and only one study (15) more than 1000 cases.

[Table 2](#T2){ref-type="table"} gives the adjustment variables used and the definitions of never smokers used in the studies.

###### Potential confounding variables adjusted for and definition of never smoker.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study\   Author         Variables adjusted for                                                                                           Definition of never smokers ^[a](#fn20){ref-type="other"}^
  No.                                                                                                                                      
  -------- -------------- ---------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------
  1        Lebowitz       None                                                                                                             Never NOS

  2        Comstock       Age, education, number of bathrooms, persons/room, children in\                                                  Never cigarettes
                          household, air conditioning, cooking fuel                                                                        

  3        Hirayama       Age of husband                                                                                                   Never cigarettes

  4        Krzyzanowski   Age                                                                                                              Never NOS

  5        Lee            Age, marital status ( [Table 3](#T3){ref-type="table"})\                                                         Never NOS
                          Age ( [Table 5](#T5){ref-type="table"}, [Table 6](#T6){ref-type="table"} and [Table 7](#T7){ref-type="table"})   

  6        Kalandidi      Age, occupation                                                                                                  Never NOS

  7        Sandler        Age, housing quality, schooling, marital status                                                                  Never any product

  8        Dayal          Age, sex, neighbourhood, heating, cooking                                                                        Never NOS

  9        Forastiere     Age, center, age x center, education                                                                             Never cigarettes

  10       Enstrom        Age ^[b](#fn21){ref-type="other"}^                                                                               Never any product ^[c](#fn22){ref-type="other"}^

  11       De Marco       Sex, childhood respiratory infections, occupational exposure,\                                                   Never smoked 20 packs of cigarettes or 360 g of tobacco\
                          socioeconomic status                                                                                             in a lifetime, or at least 1 cigarette/day or 1 cigar/week for\
                                                                                                                                           a year

  12       Celli          Age, sex, race/ethnicity, BMI, education, poverty, urban residence, high\                                        Never smoked 100 cigarettes in lifetime
                          risk industry, high risk occupation, biomass, allergy                                                            

  13       McGhee         Age, education ( [Table 3](#T3){ref-type="table"})\                                                              Never NOS
                          Age, sex, education ( [Table 4](#T4){ref-type="table"})                                                          

  14       Sezer          Wood ash, biomass ^[d](#fn23){ref-type="other"}^                                                                 Never NOS

  15       Xu             Education, occupation, family income, cooking fuels, heating in winter,\                                         Never NOS
                          ventilating fans, occupational physical activity                                                                 

  16       Yin            Age, sex, education, occupational dust exposure, indoor air pollution                                            Never NOS

  17       Zhou           Age, sex, education, BMI, family history of respiratory disease,\                                                Never NOS
                          biomass, heating fuel, ventilation in kitchen, childhood chronic cough,\                                         
                          occupational exposures                                                                                           

  18       Wu             Age, height, education level, cooking status, burning incense, tea\                                              Never smoked, on average, more than 1 cigarette/day for a\
                          consumption                                                                                                      year

  19       Jordan         Age, sex, year of study                                                                                          Never smoked at least 1 cigarette/day

  20       Lamprecht      None (COPD in [Table 3](#T3){ref-type="table"})\                                                                 Never smoked more than 20 packs in lifetime or more than 1\
                          Age, education, occupational exposure, biomass fuel use, childhood\                                              cigarette/day for a year
                          hospitalisation, comorbidity, BMI (severer COPD in [Table 3](#T3){ref-type="table"})                             

  21       Chen           None                                                                                                             Never cigarettes

  22       He             Age, sex, marital status, occupation, education, alcohol, diastolic blood\                                       Never smoked 100 cigarettes in lifetime
                          pressure, triglyceride and total cholesterol levels, BMI                                                         

  23       Waked          Age, sex, area of residence                                                                                      Never NOS

  24       Moreira        None                                                                                                             Never NOS

  25       Eze            None                                                                                                             Never NOS

  26       Hagstad        Age, sex, asthma, family history of obstructive airway disease,\                                                 Never smoked more than 1 cigarette/day for a year
                          socioeconomic group (COPD in [Table 3](#T3){ref-type="table"})\                                                  
                          None (severer COPD in [Table 3](#T3){ref-type="table"} and Ever home/work and Childhood in\                      
                          [Table 6](#T6){ref-type="table"})                                                                                

  27       Kim            Age, sex, previous diagnosis of asthma or tuberculosis, family income,\                                          Never cigarettes
                          education status                                                                                                 

  28       Tan            Age, education, childhood respiratory illness, heart disease,\                                                   Never smoked more than 1 cigarette/day for a year
                          hypertension or diabetes, asthma, BMI, exposure to organic dust,\                                                
                          inorganic dust, gases and vapours, biomass cooking and heating for\                                              
                          ≥ 10 years, TB                                                                                                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Never any product = never smoked cigarettes, pipes or cigars; Never NOS = never smoked, product unspecified;

^b^ Results adjusted for more variables not used as adjustment included health status

^c^ Questions on pipe and cigar smoking were asked at baseline, but not at the follow-up interviews

^d^ The cases and controls were matched on age

Five studies (1, 20, 21, 24, 25) made no adjustment for any potential confounding variables, while some others made little or no adjustment for such variables as occupation, education, diet and family history of disease, which may differ between smoking and non-smoking households ^[@ref-64]^. Failure to adjust for household size, where the index of exposure is based on presence of a smoker in the household, was also common. Where adjustment was carried out, all but four studies considered age, although study 3 adjusted for the husband's age rather than the subject's.

Fifteen studies were of never smokers, though only three of these made it clear they were never smokers of cigarettes, pipes or cigars. Five studies were of never cigarette smokers (i.e. they may have included some pipe or cigar only smokers), the remaining eight allowing a minimal smoking history, such as smoking less than 1 cigarette a day or less than 100 cigarettes in life.

Main exposure index
-------------------

The main meta-analyses use an exposure index that relates as closely as possible to ever smoking by the spouse. [Table 3](#T3){ref-type="table"} shows the definitions of ETS exposure used for the main index. This was based on smoking by the spouse for five studies, and on smoking by cohabitants for a further 13 (although study 13 only included participants who had lived with a smoker 10 years previously, and study 20 only considered ETS exposure in the home in the two weeks prior to the study). For the remaining studies, the index was based on exposure in the home and at work (studies 4, 12, 17, 18 and 27) or on a combination of exposure from any source (studies 11, 15, 19, 21 and 25).

###### COPD among never smokers and smoking by the spouse or household member ^[a](#fn24){ref-type="other"}^.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study\                                         Author         Type ^[b](#fn25){ref-type="other"}^   Sex   Definition of exposure ^[c](#fn26){ref-type="other"}^   Number of cases                            Odds ratio\                                       
  No.                                                                                                                                                                                                          (95% CI) ^[d](#fn27){ref-type="other"}^           
  ---------------------------------------------- -------------- ------------------------------------- ----- ------------------------------------------------------- ------------------------------------------ ------------------------------------------------- -------------------------------------------------
  1                                              Lebowitz       CS                                    M+F   Lives with ever smoker ^[e](#fn28){ref-type="other"}^   129                                        117                                               1.09 (0.83-1.44) ^[f](#fn29){ref-type="other"}^

  2                                              Comstock       CS                                    M     Lives with a smoker                                     23                                         7                                                 1.19 (0.50-2.86) ^[f](#fn29){ref-type="other"}^

  3                                              Hirayama       L15                                   F     Husband ever smoked                                     28                                         102                                               1.38 (0.86-2.21) ^[f](#fn29){ref-type="other"}^

  4                                              Krzyzanowski   L13                                   F     Exposure at home or\                                    26                                         6                                                 0.36 (0.15-0.86) ^[f](#fn29){ref-type="other"}^
                                                                                                            workplace                                                                                                                                            

                                                                                                      M                                                             3                                          2                                                 1.39 (0.26-7.40) ^[f](#fn29){ref-type="other"}^

  5                                              Lee            CC                                    F     Spouse smoked in\                                       4                                          13                                                1.22 (0.38-3.94) ^[f](#fn29){ref-type="other"}^
                                                                                                            marriage                                                                                                                                             

                                                                                                      M                                                             8                                          1                                                 0.34 (0.06-2.03) ^[f](#fn29){ref-type="other"}^

  6                                              Kalandidi      CC                                    F     Husband ever smoked ^[e](#fn28){ref-type="other"}^      13                                         90                                                1.38 (0.69-2.76) ^[f](#fn29){ref-type="other"}^

  7                                              Sandler        L12                                   F     Lived with a smoker                                     2                                          11                                                5.65 (1.19-26.8)

                                                                                                      M                                                             4                                          2                                                 0.93 (0.16-5.32)

  8                                              Dayal          CS                                    M+F   Lives with a smoker                                     74 ^[g](#fn30){ref-type="other"}^          145 ^[g](#fn30){ref-type="other"}^                1.40 (0.98-1.99) ^[f](#fn29){ref-type="other"}^

  9                                              Forastiere     CS                                    F     Ever married to a\                                      11                                         39                                                1.75 (0.88-3.47)
                                                                                                            cigarette smoker                                                                                                                                     

  10                                             Enstrom        L39                                   F     Spouse ever smoked ^[e](#fn28){ref-type="other"}^       45                                         128                                               1.13 (0.80-1.58)

                                                                                                      M                                                             69                                         22                                                1.27 (0.78-2.08)

  11                                             De Marco       CS                                    M+F   4+ hours per day\                                       129                                        27                                                1.14 (0.74-1.77) ^[f](#fn29){ref-type="other"}^
                                                                                                            exposure on most\                                                                                                                                    
                                                                                                            days/nights in previous\                                                                                                                             
                                                                                                            12 months                                                                                                                                            

  12                                             Celli          CS                                    M+F   Lives with a smoker\                                    327 ^[g](#fn30){ref-type="other"}^         86 ^[g](#fn30){ref-type="other"}^                 0.88 (0.57-1.36)
                                                                                                            who smokes in the\                                                                                                                                   
                                                                                                            home, or exposed at\                                                                                                                                 
                                                                                                            work at least 1 hour\                                                                                                                                
                                                                                                            per day                                                                                                                                              

  13                                             McGhee         CC                                    F     Lived with a smoker\                                    15                                         27                                                2.90 (1.34-6.29)
                                                                                                            10 yrs ago                                                                                                                                           

                                                                                                      M                                                             69                                         27                                                1.67 (0.95-2.94)

  14                                             Sezer          CC                                    F     Lived with a smoker for\                                13                                         61                                                2.57 (1.04-6.36) ^[f](#fn29){ref-type="other"}^
                                                                                                            at least 10 yrs                                                                                                                                      

  15                                             Xu             CC                                    M+F   Spent 15+ minutes, 3+\                                  Total 1097                                 0.95 (0.79-1.16)                                  
                                                                                                            times per week in room\                                                                                                                              
                                                                                                            with smoker at any time\                                                                                                                             
                                                                                                            in life                                                                                                                                              

  16                                             Yin            CS                                    M+F   Lived with a smoker                                     195                                        234                                               0.95 (0.77-1.18) ^[f](#fn29){ref-type="other"}^

  17                                             Zhou           CS                                    M+F   Exposure at home or\                                    119 ^[g](#fn30){ref-type="other"}^         525 ^[g](#fn30){ref-type="other"}^                1.34 (1.08-1.65) ^[f](#fn29){ref-type="other"}^
                                                                                                            workplace                                                                                                                                            

  18                                             Wu             CC                                    F     Exposure at home\                                       41                                         127                                               2.20 (1.39-3.49) ^[f](#fn29){ref-type="other"}^
                                                                                                            (including childhood) or\                                                                                                                            
                                                                                                            workplace                                                                                                                                            

  19                                             Jordan         CS                                    M+F   1+ hours of exposure\                                   Total 779 ^[g](#fn30){ref-type="other"}^   1.11 (0.95-1.30) ^[f](#fn29){ref-type="other"}^   
                                                                                                            per week                                                                                                                                             

  20                                             Lamprecht      CS                                    M+F   Exposure at home in\                                    423                                        100                                               0.89 (0.70-1.20) ^[f](#fn29){ref-type="other"}^
                                                                                                            previous 2 weeks                                                                                                                                     

  21                                             Chen           CS                                    M+F   Exposure at home,\                                      85                                         64                                                1.82 (1.30-2.54) ^[f](#fn29){ref-type="other"}^
                                                                                                            workplace or other\                                                                                                                                  
                                                                                                            places                                                                                                                                               

  22                                             He             L17                                   M+F   Exposure at home for\                                   10                                         4                                                 1.67 (0.49-5.78)
                                                                                                            15+ minutes per day,\                                                                                                                                
                                                                                                            1+ days per week for\                                                                                                                                
                                                                                                            2+ years ^[h](#fn31){ref-type="other"}^                                                                                                              

  23                                             Waked          CS                                    M+F   Lives with a smoker                                     Total 25                                   1.23 (0.55-2.74) ^[f](#fn29){ref-type="other"}^   

  24                                             Moreira        CS                                    F     Lives with a smoker                                     Total 43                                   No significant\                                   
                                                                                                                                                                                                               difference in\                                    
                                                                                                                                                                                                               number of\                                        
                                                                                                                                                                                                               years exposure,\                                  
                                                                                                                                                                                                               or proportion\                                    
                                                                                                                                                                                                               exposed to\                                       
                                                                                                                                                                                                               straw cigarettes ^[i](#fn32){ref-type="other"}^   

  25                                             Eze            CS                                    M+F   Exposure at home,\                                      293                                        151                                               1.00 (0.81-1.24) ^[f](#fn29){ref-type="other"}^
                                                                                                            workplace or other\                                                                                                                                  
                                                                                                            places in previous year                                                                                                                              

  26                                             Hagstad        CS                                    M+F   Ever lived with a\                                      25                                         64                                                1.38 (0.84-2.27)
                                                                                                            smoker ^[j](#fn33){ref-type="other"}^                                                                                                                

  27                                             Kim            CS                                    M+F   Exposure at home or\                                    248                                        75                                                0.85 (0.60-1.21) ^[f](#fn29){ref-type="other"}^
                                                                                                            workplace                                                                                                                                            

  28                                             Tan            CS                                    F     Lived with a smoker in\                                 M&F 94                                     M&F 12                                            2.20 (1.03-4.71)
                                                                                                            previous 2 weeks                                                                                                                                     

                                                                                                      M                                                             1.01 (0.27-3.76)                                                                             

  Severer COPD ^[k](#fn34){ref-type="other"}^:                                                                                                                                                                                                                   

  17                                             Zhou           CS                                    M+F   Exposure at home or\                                    89                                         379                                               1.27 (1.00-1.63) ^[f](#fn29){ref-type="other"}^
                                                                                                            workplace ^[j](#fn33){ref-type="other"}^                                                                                                             

  19                                             Jordan         CS                                    M+F   1+ hours of exposure\                                   Total 334 ^[g](#fn30){ref-type="other"}^   1.13 (0.84-1.51) ^[f](#fn29){ref-type="other"}^   
                                                                                                            per week                                                                                                                                             

  20                                             Lamprecht      CS                                    F     Exposure at home in\                                    Total 159                                  1.53 (0.98-2.41)                                  
                                                                                                            previous 2 weeks                                                                                                                                     

                                                                                                      M                                                             Total 67                                   0.97 (0.40-2.40)                                  

  26                                             Hagstad        CS                                    M+F   Ever lived with a\                                      11                                         35                                                2.46 (1.24-4.88) ^[f](#fn29){ref-type="other"}^
                                                                                                            smoker ^[j](#fn33){ref-type="other"}^                                                                                                                

  28                                             Tan            CS                                    F     Lives with a smoker                                     M&F 94                                     M&F 4                                             1.65 (0.46-5.88)

                                                                                                      M                                                             0.69 (0.08-6.31)                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Or nearest equivalent to spouse or household member (see text and Table)

^b^ Study types are CC = case-control, CS = cross-sectional, L = longitudinal. For longitudinal studies, number of years follow-up is shown

^c^ Comparison is with those not exposed as defined, except where indicated otherwise

^d^ RRs from longitudinal studies are taken as being equivalent to ORs

^e^ Separate results also available for current smoker and exsmoker

^f^ OR and/or CI estimated from data provided

^g^ Approximate estimates

^h^ Compares exposed at home only to unexposed. Excludes those exposed at work

^i^ A straw cigarette is a handful of tobacco, wrapped in a corn husk; study not included in meta-analysis

^j^ Compared to subjects not exposed to any source of ETS; results also available for current or former exposure

^k^ Results not included in the meta-analysis in [Figure 2](#f2){ref-type="fig"}

Although most studies presented results comparing participants who were exposed or unexposed to ETS, some required a minimum level before a subject could be classified as exposed. In study 19, exposure had to be for at least one hour per week, while study 12 specified living with a smoker who smoked in the home or exposure at work for at least one hour per day. In studies 20 and 28, exposure had to have been in the previous two weeks, while participants in study 25 had to have had regular exposure in the previous year. In study 22 exposure had to be for 15+ minutes per day at least once per week for two or more years, while in study 15 the minimum requirement was 15 minutes or more, three or more times per week. In study 11, participants were only considered to have been exposed if they reported four or more hours of exposure on most days or nights in the previous year. Finally, study 14 required 10 years of exposure.

[Table 3](#T3){ref-type="table"}, supported by [Figure 2](#f2){ref-type="fig"}, also presents the ORs for the main exposure index, while [Table 4](#T4){ref-type="table"} presents the results of meta-analyses, and [Table 5](#T5){ref-type="table"} the dose-response data.

![Forest plot for the main index, by region.\
Individual study estimates of the OR and its 95%CI are shown separately by region, sorted in increasing order of OR. These are shown as numbers, and also graphically on a logarithmic scale. Random-effects estimates of ORs and 95%CIs are also shown for each region combined and overall. Studies are identified by the study number shown in [Table 1](#T1){ref-type="table"}. In the graphical representation, ORs are indicated by a square, with the area of the square proportional to the weight.](f1000research-7-24188-g0001){#f2}

###### Meta-analyses of COPD ^[a](#fn35){ref-type="other"}^ risk among never smokers and smoking by spouse or household member ^[b](#fn36){ref-type="other"}^.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                     Fixed-effect       Random-\            Publication\   Heterogeneity ^[c](#fn37){ref-type="other"}^   
                                                                                        effects             bias                                                          
  ------------------------------------------------------------- ---- ------------------ ------------------- -------------- ---------------------------------------------- -----------
  All COPD                                                      33   1.14 (1.07-1.21)   1.20 (1.08-1.34)    \<0.1          1.99                                           \<0.001

  *By continent*                                                                                                                                                          

  North America                                                 10   1.19 (1.02-1.38)   1.19 (1.01-1.41)    NS             1.08                                           NS

  Asia                                                          10   1.18 (1.07-1.30)   1.34 (1.08-1.67)    \<0.1          3.83                                           \<0.001

  Europe ^[h](#fn41){ref-type="other"}^                         11   1.10 (0.98-1.24)   1.14 (0.93-1.39)    NS             1.53                                           NS

  Multicountry                                                  2    0.95 (0.76-1.20)   0.95 (0.76-1.20)    \-             0.90                                           NS

                                                                                        *Between*\                         *1.13*                                         *NS*
                                                                                        *continents*                                                                      

  *By publication period*                                                                                                                                                 

  1976--1990                                                    10   1.12 (0.91-1.37)   1.11 (0.81-1.52)    NS             1.52                                           NS

  1991--2005                                                    8    1.28 (1.09-1.50)   1.30 (1.07-1.59)    \<0.1          1.40                                           NS

  2006--2015                                                    15   1.11 (1.03-1.20)   1.19 (1.03-1.37)    \<0.1          2.70                                           \<0.001

                                                                                        *Between periods*                  *1.18*                                         *NS*

  *By study type*                                                                                                                                                         

  Longitudinal                                                  8    1.18 (0.94-1.47)   1.18 (0.83-1.67)    NS             1.71                                           NS

  Case-control                                                  8    1.20 (1.02-1.40)   1.55 (1.04-2.32)    NS             3.36                                           \<0.01

  Cross-sectional                                               17   1.12 (1.04-1.21)   1.14 (1.02-1.27)    NS             1.72                                           \<0.05

                                                                                        *Between types*                    *0.34*                                         *NS*

  *By sex*                                                                                                                                                                

  Males                                                         7    1.29 (0.94-1.76)   1.29 (0.94-1.76)    NS             0.55                                           NS

  Females                                                       11   1.50 (1.25-1.81)   1.59 (1.16-2.19)    NS             2.40                                           \<0.01

  Both                                                          15   1.08 (1.01-1.16)   1.10 (0.99-1.22)    NS             1.81                                           \<0.05

                                                                                        *Between sexes*                    *5.57*                                         *\<0.01*

  *By diagnosis*                                                                                                                                                          

  Mortality ^[i](#fn42){ref-type="other"}^ or hospitalisation   11   1.37 (1.13-1.66)   1.40 (1.12-1.74)    NS             1.13                                           NS

  GOLD Stage 1+                                                 10   1.09 (1.01-1.19)   1.11 (0.97-1.27)    NS             2.22                                           \<0.05

  Other                                                         12   1.15 (1.02-1.29)   1.23 (0.97-1.56)    NS             2.54                                           \<0.01

                                                                                        *Between*\                         *2.24*                                         *NS*
                                                                                        *diagnoses*                                                                       

  *By method for taking*\                                                                                                                                                 
  *asthma into account*                                                                                                                                                   

  Included                                                      4    1.19 (1.00-1.41)   1.19 (1.00-1.41)    NS             *0.45*                                         *NS*

  Adjusted for                                                  4    0.94 (0.77-1.15)   1.00 (0.72-1.39)    NS             *1.76*                                         *NS*

  Excluded                                                      4    1.11 (0.99-1.26)   1.24 (0.93-1.65)    NS             *3.63*                                         *\<0.05*

  Ignored                                                       21   1.18 (1.08-1.30)   1.27 (1.07-1.50)    NS             *2.08*                                         *\<0.01*

                                                                                        *Between*\                         *1.49*                                         *NS*
                                                                                        *methods*                                                                         

  *By number of cases*\                                                                                                                                                   
  *estimate is based on*                                                                                                                                                  

  \<50                                                          11   1.29 (0.97-1.71)   1.26 (0.83-1.92)    NS             1.85                                           \<0.05

  50--149                                                       9    1.62 (1.35-1.96)   1.62 (1.35-1.96)    NS             0.53                                           NS

  150+                                                          13   1.07 (1.00-1.15)   1.08 (0.97-1.20)    NS             1.97                                           \<0.05

                                                                                        *Between*\                         *8.65*                                         *\<0.001*
                                                                                        *numbers*                                                                         

  *By extent of confounder*\                                                                                                                                              
  *adjustment*                                                                                                                                                            

  Unadjusted for age                                            6    1.11 (0.98-1.25)   1.15 (0.94-1.42)    NS             2.55                                           \<0.05

  Adj. for age+ \<5 variables                                   18   1.16 (1.05-1.28)   1.26 (1.06-1.49)    NS             1.75                                           \<0.05

  Adj. for age+ 5+ variables                                    9    1.13 (1.00-1.27)   1.20 (0.95-1.53)    NS             2.61                                           \<0.01

                                                                                        *Between groups*                   *0.16*                                         *NS*

  *By definition of never*\                                                                                                                                               
  *smoker*                                                                                                                                                                

  Never any product                                             4    1.22 (0.93-1.61)   1.28 (0.88-1.87)    NS             1.34                                           NS

  Never, product unstated                                       15   1.10 (1.01-1.20)   1.16 (0.99-1.36)    NS             2.15                                           \<0.01

  Other                                                         14   1.17 (1.06-1.30)   1.25 (1.05-1.50)    NS             2.18                                           \<0.01

                                                                                        *Between*\                         *0.63*                                         *NS*
                                                                                        *definitions*                                                                     

  *By definition of exposure*                                                                                                                                             

  Spouse specifically                                           7    1.26 (1.02-1.55)   1.26 (1.02-1.55)    NS             0.60                                           NS

  Other lives with smoker                                       15   1.14 (1.02-1.29)   1.31 (1.08-1.59)    \<0.01         1.85                                           \<0.05

  Other                                                         11   1.11 (1.03-1.21)   1.13 (0.95-1.34)    NS             3.31                                           \<0.001

                                                                                        *Between*\                         *0.55*                                         *NS*
                                                                                        *definitions*                                                                     

  All severer COPD                                              7    1.29 (1.10-1.52)   1.29 (1.10-1.52)    NS             0.94                                           NS
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Definition of COPD as shown in the body of [Table 1](#T1){ref-type="table"}, severer COPD in footnotes to [Table 1](#T1){ref-type="table"}. Data as shown in [Table 3](#T3){ref-type="table"}

^b^ Or nearest equivalent to spouse or household member (see text and [Table 3](#T3){ref-type="table"})

^c^ Heterogeneity relates to variation between studies within subgroup, except for results given in italics which relate to heterogeneity between subgroups

^d^ N number of estimates in meta-analysis

^e^ Egger test p expressed as \<0.001, \<0.01, \<0.05, \<0.1 or NS (p≥0.1)

^f^ DF degrees of freedom

^g^ p expressed as \<0.001, \<0.01, \<0.05, \<0.1 or NS (p≥0.1)

^h^ Includes one study from Turkey and one from Lebanon

^i^ Including study 22

###### Dose-response evidence for COPD among never smokers for smoking by spouse or household member.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study\          Author      Type ^[a](#tfn1){ref-type="other"}^   Sex   Exposure\      Level                                         No. of\                               Odds ratio\                                        Trend p ^[c](#tfn3){ref-type="other"}^
  No.                                                                     Source                                                       cases                                 (95% CI) ^[b](#tfn2){ref-type="other"}^            
  --------------- ----------- ------------------------------------- ----- -------------- --------------------------------------------- ------------------------------------- -------------------------------------------------- ----------------------------------------
  COPD:                                                                                                                                                                                                                         

  3               Hirayama    L15                                   F     Husband        Never smoked\                                 28\                                   1.00\                                              \
                                                                                         Ex smoker or 1--19/day\                       65\                                   1.29 (0.79-2.12) ^[d](#tfn4){ref-type="other"}^\   \
                                                                                         20+/day                                       37                                    1.60 (0.92-2.78) ^[d](#tfn4){ref-type="other"}^    NS

  6               Kalandidi   CC                                    F     Husband        Never smoked\                                 13\                                   1.00\                                              \
                                                                                         Daily consumption\                            \                                     \                                                  \
                                                                                         ≤1 pack/day\                                  35\                                   2.5 (1.3-5.0)\                                     \
                                                                                         ≥1 pack/day\                                  37\                                   1.5 (0.8-2.7)\                                     NS\
                                                                                         Lifelong consumption\                         \                                     \                                                  \
                                                                                         ≤300,000 cigs\                                52\                                   1.30 (0.64-2.64) ^[d](#tfn4){ref-type="other"}^\   \
                                                                                         300,000+ cigs                                 38                                    1.70 (0.72-4.03) ^[d](#tfn4){ref-type="other"}^    NS

  8               Dayal       CS                                    M+F   Cohabitants    No smoker\                                    74 ^[e](#tfn5){ref-type="other"}^\    1.00\                                              \
                                                                                         ≤1 pack/day ^[f](#tfn6){ref-type="other"}^\   76 ^[e](#tfn5){ref-type="other"}^\    1.16 (0.78-1.72)\                                  \
                                                                                         \>1 pack/day ^[f](#tfn6){ref-type="other"}^   69 ^[e](#tfn5){ref-type="other"}^     1.86 (1.21-2.86)                                   ++

  10              Enstrom     L39                                   F\    Husband\       Per level ^[g](#tfn7){ref-type="other"}^\     173\                                  0.99 (0.92-1.06)\                                  NS\
                                                                    M     Wife           Per level ^[g](#tfn7){ref-type="other"}^      91                                    1.06 (0.91-1.25)                                   NS

  13              McGhee      CC                                    M+F   Cohabitants    No smoker\                                    84\                                   1.00\                                              \
                                                                                         1 smoker\                                     54 ^[h](#tfn8){ref-type="other"}^\    1.85 (1.14-3.00)\                                  \
                                                                                         2+ smokers                                    \                                     2.51 (1.22-5.18)                                   ++

  14              Sezer       CC                                    F     Cohabitants    \<10 years\                                   13\                                   1.00\                                              \
                                                                                         10--19 years\                                 12\                                   1.19 (0.58-5.68)\                                  \
                                                                                         20--29 years\                                 20\                                   2.46 (0.83-7.33)\                                  \
                                                                                         30+ years                                     29                                    4.96 (1.65-14.86)                                  ++

  16              Yin         CS                                    M+F   Cohabitants    No smoker\                                    195\                                  1.00\                                              \
                                                                                         1 smoker\                                     201\                                  0.96 (0.77-1.20)\                                  \
                                                                                         2+ smokers\                                   33\                                   0.92 (0.62-1.36)\                                  NS\
                                                                                         \                                             \                                     \                                                  \
                                                                                         \<2 years of 40 hours/wk\                     273\                                  1.00\                                              \
                                                                                         2--5 years of 40 hours/wk\                    73\                                   1.11 (0.84-1.47)\                                  \
                                                                                         5+ years of 40 hours/wk                       83                                    1.60 (1.23-2.10)                                   ++

  18              Wu          CC                                    F     Lifetime\      No exposure\                                  41\                                   1.00\                                              \
                                                                          cohabitants\   \                                             \                                     \                                                  \
                                                                          and co-\       \<32 years\                                   58\                                   1.86 (1.10-3.17) ^[d](#tfn4){ref-type="other"}^\   \
                                                                          workers        32+ years                                     69                                    2.53 (1.51-4.26) ^[d](#tfn4){ref-type="other"}^    + ^[i](#tfn25){ref-type="other"}^

  19              Jordan      CS                                    M+F   Any\           Total\                                        779 ^[e](#tfn5){ref-type="other"}^\   \                                                  \
                                                                          exposure       No exposure\                                  \                                     1.00\                                              \
                                                                                         1--19 hours/wk\                               \                                     1.11 (0.94-1.31)\                                  \
                                                                                         20+ hours/wk                                  \                                     1.10 (0.81-1.49)                                   NS

  22              He          L17                                   M+F   Cohabitants\   Score 0 ^[f](#tfn6){ref-type="other"}^\       10\                                   1.00\                                              \
                                                                          and co-\       Score 1-2\                                    8\                                    1.52 (0.57-4.04)\                                  \
                                                                          workers        Score 3-4\                                    13\                                   2.32 (0.98-5.50)\                                  \
                                                                                         Score 5-6                                     5                                     5.01 (1.65-15.24)                                  ++

  27              Kim         CS                                    M+F   Home or\       Total\                                        323\                                  \                                                  \
                                                                          workplace      No exposure\                                  \                                     1.00\                                              \
                                                                                         ≤6 hours/day\                                 \                                     0.83 (0.58-1.19)\                                  \
                                                                                         \>6 hours/day                                 \                                     1.75 (0.47-6.59)                                   NS

  Severer COPD:                                                                                                                                                                                                                 

  19              Jordan      CS                                    M+F   Any\           Total\                                        334 ^[e](#tfn5){ref-type="other"}^\   \                                                  \
                                                                          exposure       No exposure\                                  \                                     1.00\                                              \
                                                                                         1-19 hours/wk\                                \                                     1.10 (0.81-1.49)\                                  \
                                                                                         20+ hours/wk                                  \                                     1.33 (0.74-2.38)                                   NS
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Study types are CC = case-control, CS = cross-sectional, L = longitudinal. For longitudinal studies, number of years follow-up is shown

^b^ RRs from longitudinal studies are taken as being equivalent to ORs

^c^ NS p≥0.05, + p\<0.05, ++ p\<0.01

^d^ OR and/or CI estimated from data provided

^e^ Approximate estimates

^f^ Sum of smoking levels for all cohabitants

^g^ For husband smoking, there were 8 levels: never, former, current pipe/cigar, and current cigs/day 1-9, 10-19, 20, 21-39 and 40+. For wife smoking there were 7 levels, as for husband except with no level for pipe/cigar

^h^ Number of cases is for the exposed groups combined

^i^ Trend estimated from data provided

^j^ Sum of scores for exposure at home (0 = no exposure, 1 = \<4 pack years, 2 = 4 to \<8 pack years, 3 = ≥8 pack years) and at work (0 = no exposure, 1 = \<5, 2 = 5 to \<15, 3 = ≥15, calculated from (pack years x smokers x hours/day)/100

From [Table 3](#T3){ref-type="table"} it can be seen that, of the 33 individual OR estimates given for COPD, 24 are above 1.00, seven of these increases being significant at p\<0.05. Eight studies reported an OR below 1.00, but only in study 4 for females was the reduction statistically significant. Study 25 reported an OR of 1.00, while study 24, excluded from the meta-analyses, did not present an OR but reported no significant relationship with duration or type of exposure. In addition, five studies presented a total of seven OR estimates for severer COPD, with five estimates above 1.00 (one significantly so and one marginally significant) and two non-significantly below 1.00.

[Table 4](#T4){ref-type="table"} demonstrates that the overall evidence for the main exposure index shows some increased risk of COPD, with the random-effects OR, based on 33 independent estimates, being 1.20 (95% CI 1.08-1.34) with no clear evidence of publication bias (0.05\<p\<0.1), but clear heterogeneity (p\<0.001). The largest contributors to this were the high ORs for studies 18 and 21 and in females for study 13 and the low OR in females for study 4.

Although there was no significant heterogeneity by continent, a significant increase was seen for North America (1.19, 1.01-1.41, n = 10) and Asia (1.34, 1.08-1.67, n = 10), but not for other locations. There was no significant heterogeneity by period of publication or study type. There was evidence of heterogeneity by sex (p\<0.01), with a significant increase only for females (1.59, 1.16-2.19, n = 11). There was no heterogeneity by aspects of diagnosis, although the estimates were highest for definitions based on mortality or hospitalisation (1.40, 1.12-1.74, n = 11). However, there was significant heterogeneity (p\<0.001) by numbers of cases, with larger ORs from studies of less than 50 cases (1.26, 0.83-1.92, n=11) and from studies of 50-149 cases (1.62, 1.35-1.96, n=9) than for studies of 150 or more cases (1.08, 0.97-1.20, n=13). There was no significant evidence of heterogeneity by extent of confounder adjustment, or by how never smokers or the exposure index were defined. For all these subgroup analyses, there was little evidence of publication bias, but evidence of heterogeneity in some subgroups.

The combined OR for severer COPD was significant (1.29, 1.10-1.52, n=7).

There was also evidence of a dose-response relationship, as shown in [Table 5](#T5){ref-type="table"}, with six of 11 studies investigating this reporting a statistically significant positive trend. Study 16 reported no trend in relation to the number of smokers in the household, but did report positive dose-response relationships for years of ETS exposure at home and at work. Study 19, which found no relationship with the main COPD outcome, also presented dose-response relationships for severer COPD, again finding no significant increase in risk with increasing exposure.

Other exposure indices
----------------------

Five studies also presented additional results for other indices of ETS exposure, as shown in [Table 6](#T6){ref-type="table"}. Four studies (16, 22, 23, 26) looked at exposure at work, all but study 23 also presenting results for combined exposure at home and at work. Study 5 produced a combined index of adulthood exposure at home or work, or during travel or leisure. Three studies (16, 23, 26) considered childhood ETS exposure, study 23 studying exposure from both the mother and the father, and also looking at parental smoking during pregnancy.

###### Odds ratio for COPD among never smokers for other indices of ETS exposure.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study\          Author    Type ^[a](#fn70){ref-type="other"}^   Sex   Number of cases   Index of exposure ^[b](#fn44){ref-type="other"}^   Odds ratio\                                                     Meta-\                                            
  No.                                                                                                                                        (95% CI) ^[c](#fn45){ref-type="other"}^                         analysis ^[d](#fn46){ref-type="other"}^           
  --------------- --------- ------------------------------------- ----- ----------------- -------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------- ---
  5               Lee       CC                                    F     7                 5                                                  Combined index of adulthood\                                    1.04 (0.34-3.20) ^[f](#fn48){ref-type="other"}^   A
                                                                                                                                             exposure at home, work, during\                                                                                   
                                                                                                                                             travel and leisure ^[e](#fn47){ref-type="other"}^                                                                 

                                                                  M     1                 3                                                                                                                  1.18 (0.19-7.42) ^[f](#fn48){ref-type="other"}^   A

  16              Yin       CS                                    M+F   225               204                                                Childhood -- home                                               0.87 (0.71-1.06) ^[f](#fn48){ref-type="other"}^   C

                                                                        240               187                                                Adulthood -- work                                               0.96 (0.78-1.19) ^[f](#fn48){ref-type="other"}^   W

                                                                        191               238                                                Adulthood - home and/or work ^[g](#fn49){ref-type="other"}^     1.24 (1.01-1.51) ^[f](#fn48){ref-type="other"}^   A

  22              He        L17                                   M+F   10                26                                                 Workplace ^[h](#fn50){ref-type="other"}^                        2.52 (1.00-6.38)                                  W

                                                                  M     8                 15                                                 Adulthood -- home and/or work                                   2.15 (0.86-5.39)                                  A

                                                                  F     2                 11                                                                                                                 3.31 (0.69-15.82)                                 A

  23              Waked     CS                                    M+F   Total 25          During pregnancy: mother                           1.59 (0.51-4.92) ^[f](#fn48){ref-type="other"}^                                                                   

                                                                                          During pregnancy: father                           1.69 (0.73-3.90) ^[f](#fn48){ref-type="other"}^                                                                   

                                                                                          Childhood: mother                                  1.17 (0.39-3.52) ^[f](#fn48){ref-type="other"}^                 C                                                 

                                                                                          Childhood: father                                  1.36 (0.61-3.07) ^[f](#fn48){ref-type="other"}^                                                                   

                                                                                          Workplace                                          0.75 (0.18-3.14) ^[f](#fn48){ref-type="other"}^                 W                                                 

  26              Hagstad   CS                                    M+F   25                78                                                 Previous workplace ^[i](#fn51){ref-type="other"}^               1.42 (0.86-2.33)                                  

                                                                        25                14                                                 Current workplace ^[i](#fn51){ref-type="other"}^                1.17 (0.58-2.36)                                  W

                                                                        25                10                                                 Previous and current workplace ^[i](#fn51){ref-type="other"}^   1.74 (0.77-3.91)                                  

                                                                        25                5                                                  Ever at home and both previous\                                 3.80 (1.29-11.20)                                 
                                                                                                                                             and current workplace ^[i](#fn51){ref-type="other"}^                                                              

                                                                        25                3                                                  Currently at home and both\                                     5.73 (1.46-22.50)                                 
                                                                                                                                             previous and current workplace ^[i](#fn51){ref-type="other"}^                                                     

                                                                        25                115                                                Ever at home and/or work ^[i](#fn51){ref-type="other"}^         1.87 (1.20-2.91) ^[f](#fn48){ref-type="other"}^   A

  Severer COPD:                                                                                                                                                                                                                                                

  26              Hagstad   CS                                    M+F   Total 27          Childhood ^[j](#fn52){ref-type="other"}^           0.62 (0.28-1.35) ^[f](#fn48){ref-type="other"}^                                                                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Study types are CC = case control, CS = cross-sectional, L = longitudinal. For longitudinal studies, number of years follow-up is shown

^b^ Comparison is with no exposure of the type specified, except where indicated otherwise

^c^ RRs from longitudinal studies are taken as being equivalent to ORs

^d^ A = Any adult, C = Childhood and W = Workplace indicate estimates included in [Table 7](#T7){ref-type="table"} meta-analysis

^e^ Comparison is with those with no exposure of any of the four types, or at most little exposure from one of them

^f^ OR and/or CI estimated from data provided

^g^ Comparison is with those with \<2 years of 40 hours per week exposure

^h^ Compares exposed at work only to unexposed. Excludes those exposed at home

^i^ Comparison group is subjects not exposed to ETS from any source

^j^ From [@ref-65]

The ORs for these other exposure indices are supported by [Figure 3](#f3){ref-type="fig"} (workplace) and [Figure 4](#f4){ref-type="fig"} (overall adult), while [Table 7](#T7){ref-type="table"} presents the results of meta-analyses. Note that [Figure 4](#f4){ref-type="fig"}, and the meta-analyses for overall adult exposure, consider not only the ORs indicated in [Table 6](#T6){ref-type="table"}, but also include estimates from [Table 3](#T3){ref-type="table"} for those ten studies (4, 11, 12, 15, 17, 18, 19, 21, 25, 27) for which the exposure was at least from home and work.

![Forest plot for workplace exposure.\
Individual study estimates of the OR and its 95%CI are shown sorted in increasing order of OR. These are shown as numbers, and also graphically on a logarithmic scale. Random-effects estimates of ORs and 95%CIs are also shown. Studies are identified by the study number shown in [Table 1](#T1){ref-type="table"}. In the graphical representation, ORs are indicated by a square, with the area of the square proportional to the weight.](f1000research-7-24188-g0002){#f3}

![Forest plot for overall adult exposure.\
Individual study estimates of the OR and its 95%CI are shown sorted in increasing order of OR. These are shown as numbers, and also graphically on a logarithmic scale. Random-effects estimates of ORs and 95%CIs are also shown. Studies are identified by the study number shown in [Table 1](#T1){ref-type="table"}. In the graphical representation, ORs are indicated by a square, with the area of the square proportional to the weight.](f1000research-7-24188-g0003){#f4}

###### Meta-analyses of COPD ^[a](#tfn21){ref-type="other"}^ risk among never smokers for other indices of ETS exposure.

  -----------------------------------------------------------------------------------------------------------------------------------
                                                       Fixed-effect       Random-effects     Publication\   Heterogeneity   
                                                                                             bias                           
  ----------------------------------------------- ---- ------------------ ------------------ -------------- --------------- ---------
  Workplace                                       4    1.01 (0.83-1.23)   1.12 (0.77-1.64)   NS             1.43            NS

  Overall adult ^[f](#tfn26){ref-type="other"}^   17   1.16 (1.07-1.25)   1.20 (1.03-1.39)   NS             2.65            \<0.001

  Child ^[g](#tfn27){ref-type="other"}^           2    0.88 (0.72-1.07)   0.88 (0.72-1.07)   \-             0.27            NS
  -----------------------------------------------------------------------------------------------------------------------------------

^a^ Definition of COPD as shown in the body of [Table 1](#T1){ref-type="table"}. Data as shown in [Table 6](#T6){ref-type="table"} excluding severer COPD

^b^ Number of estimates in meta-analysis

^c^ Egger test p expressed as \<0.001, \<0.01, \<0.05, \<0.1 or NS (p≥0.1)

^d^ Degrees of freedom

^e^ p expressed as \<0.001, \<0.01, \<0.05, \<0.1 or NS (p≥0.1)

^f^ Index includes "home or workplace" or combined index of any adulthood exposure. Note that this meta-analysis not only includes those estimates marked with an A in [Table 6](#T6){ref-type="table"}, but also includes estimates from [Table 3](#T3){ref-type="table"} for studies 4, 11, 12, 15, 17, 18, 19, 21, 25 and 27

^g^ Preferring exposure from the mother in study 23. Estimates would be 0.89 (0.74-1.08) fixed and 0.91 (0.70-1.18) random, preferring exposure from the father

Of the four ORs included in the meta-analysis of COPD for exposure at work, two were above 1.00, one of borderline statistical significance, and two were below 1.00, the combined estimate being 1.12 (0.77-1.64). Note that in study 26 there was a choice of workplace OR estimates, with the meta-analysis including that for current exposure. Using estimates for previous or ever exposure would not have affected the conclusion that there was no clear relationship of COPD to workplace ETS exposure.

Of the 17 ORs included in the meta-analysis for overall adult exposure, 12 were above 1.00, five significantly so, with one equal to 1.00, and four less than 1.00. The combined estimate of 1.20 (1.03-1.39) was also significantly increased.

There was no clear association of COPD with childhood ETS exposure, with none of the ORs shown in [Table 6](#T6){ref-type="table"} being significant. Only two estimates could be included in the meta-analysis, giving an overall estimate of 0.88 (0.72-1.07).

There was no significant evidence of publication bias for workplace or adult exposure, the data being too limited to assess this for childhood exposure. However, there was evidence of heterogeneity (p\<0.01) for overall adult ETS exposure.

The limited further dose-response data shown in [Table 8](#T8){ref-type="table"} added little to the data already shown in [Table 5](#T5){ref-type="table"}.

###### Dose-response evidence for COPD among never smokers for other indices of exposure.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study\   Author   Type ^[a](#tfn28){ref-type="other"}^   Sex   Exposure                                                             No. of\   Odds ratio\         Trend\
  No.                                                                                                                                 cases     (95% CI)            p ^[b](#tfn29){ref-type="other"}^
  -------- -------- -------------------------------------- ----- ------------------------ ------------------------------------------- --------- ------------------- ------------------------------------
  5        Lee      CC                                     F     Combined index of\       Score 0-1 ^[c](#tfn30){ref-type="other"}^   7         1.00                
                                                                 adulthood exposure\                                                                                
                                                                 at home, work, during\                                                                             
                                                                 travel and leisure                                                                                 

                                                                                          Score 2-4                                   4         1.05 (0.29-3.75)    

                                                                                          Score 5-12                                  1         1.03 (0.12-8.85)    NS ^[d](#tfn31){ref-type="other"}^

                                                           M                              Score 0-1                                   1         1.00                

                                                                                          Score 2-4                                   2         0.83 (0.07-9.56)    

                                                                                          Score 5-12                                  1         1.90 (0.11-32.61)   NS ^[d](#tfn31){ref-type="other"}^

  16       Yin      CS                                     M+F   Childhood                No smoker                                   225       1.00                

                                                                                          1 smoker                                    157       0.89 (0.72-1.10)    

                                                                                          2+ smokers                                  47        0.81 (0.58-1.12)    NS

                                                                 Co-workers               No smoker                                   240       1.00                

                                                                                          1 smoker                                    15        0.88 (0.51-1.52)    

                                                                                          2+ smokers                                  172       0.97 (0.78-1.20)    NS

                                                                                          \<2 years of\                               286       1.00                
                                                                                          40 hours/wk                                                               

                                                                                          2--5 years of\                              65        1.35 (1.01-1.80)    
                                                                                          40 hours/wk                                                               

                                                                                          5+ years of\                                78        1.50 (1.14-1.97)    ++
                                                                                          40 hours/wk                                                               

                                                                 Cohabitants and\         \<2 years of\                               191       1.00                
                                                                 co-workers               40 hours/wk                                                               

                                                                                          2--5 years of\                              82        0.95 (0.72-1.24)    
                                                                                          40 hours/wk                                                               

                                                                                          5+ years of\                                156       1.48 (1.18-1.85)    ++
                                                                                          40 hours/wk                                                               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Study types are CC = case-control, CS = cross-sectional

^b^ NS = p≥0.05, + = p\<0.05, ++ = p\<0.01

^c^ Based on sum of 0 = not at all, 1 = little, 2 = average, 3 = a lot for each source of exposure

^d^ Trend estimated from data provided

Discussion
==========

We rejected papers for various appropriate reasons. These included the following: failing to give results for an endpoint equivalent to COPD; giving results only for COPD exacerbation or prognosis; not presenting results for never smokers; describing studies without a control group; not presenting results for those unexposed to ETS; and presenting less useful results than reported in another publication.

Twenty-eight epidemiological studies did qualify for inclusion, and from 33 estimates of the risk of COPD associated with ever having a spouse who smoked, or the nearest equivalent ETS exposure index available, random-effects meta-analysis gave a significantly increased OR estimate of 1.20 (1.08-1.34). There was also some evidence of dose-response. While the clear relationship of smoking with COPD ^[@ref-31]^ makes it plausible that some effect will also be evident for ETS, one must emphasize that exposure is much less than from active smoking, as noted in the Introduction. Also, various limitations of the evidence, discussed below, make it difficult to estimate reliably the true extent of any causal relationship. However, one should also take into account the evidence of a relationship between ETS and wheezing ^[@ref-46],\ [@ref-66]^, a symptom of COPD.

Few cases
---------

Though four studies involved more than 500 cases, with the maximum 1097 in study 15, as many as ten of the 28 studies involved less than 100 cases, the quite small number of cases making it difficult to detect potential effects reliably.

Publication bias
----------------

The observation that ORs are only modestly raised for studies with larger numbers of cases but are greater for smaller studies suggests the possibility of publication bias, with authors being more likely to report stronger relationships. However formal tests for publication bias ^[@ref-54]^ showed no clear evidence of its existence. One must note, though, that various large longitudinal studies, e.g. [@ref-67]-- [@ref-70], reported results relating ETS to smoking-related diseases such as lung cancer or heart disease, but did not do so for COPD. If any relationship had been seen, these studies might well have been reported.

Misclassification of smoking status
-----------------------------------

No study validated the lifelong non-smoking status of their participants, although study 18 did verify current active and passive exposure in a random sample of participants by measuring urinary cotinine levels. As some current and past smokers deny smoking when interviewed ^[@ref-71]^, and as the smoking habits of spouses or household members are clearly correlated ^[@ref-47]^, misclassification of even a few ever smokers as never smokers can cause relevant bias ^[@ref-72]^, especially when, as is the case with COPD, the association with smoking is strong ^[@ref-31]^.

Weaknesses in longitudinal studies
----------------------------------

All the longitudinal studies considered involved follow-up for at least 12 years. Of the five studies, three (studies 3, 7 and 10) assumed spousal smoking was unchanged during follow-up, only studies 4 and 22 collecting information on smoking status at multiple time points.

All these studies only considered COPD deaths which occurred in the original study area.

Inappropriate controls in case-control studies
----------------------------------------------

Although three case-control studies used population controls, the remaining three used control groups unlikely to be representative of the population from which the cases derived. Studies 6 and 14 used visitors to the hospital attended by the cases, and study 13 used as a control a person identified by the informant of a death as a "living person about the same age who was well known to the informant", the informant then being asked about the lifestyle 10 years earlier of both decedent and control.

Weakness of cross-sectional studies
-----------------------------------

Over half of the studies were of cross-sectional design, a design limited by difficulties in determining whether ETS exposure or disease onset occurred first.

Poor control for potential confounding variables
------------------------------------------------

As noted above, some studies made little or no adjustment for variables likely to differ between smoking and non-smoking households. Though ORs for the main exposure index did not vary significantly by extent of adjustment, it should be noted that adjustment for dietary variables and education explains a substantial part of the association of lung cancer with spousal smoking ^[@ref-45]^. The same may be the case for COPD.

Variation and appropriateness of diagnostic criteria
----------------------------------------------------

Definitions of COPD used were all consistent with the inclusion criteria. However, they still varied somewhat between study, further adding uncertainty to the meta-analysis results. Even given the inclusion criteria, there are doubts about the appropriateness of the diagnostic criteria used in some studies. In study 8, for example, the definition included asthma as well as chronic bronchitis and emphysema, the diagnosis being reported by the head of the household, and not necessarily made by a doctor.

Misclassification of ETS exposure
---------------------------------

While random errors in determining ETS exposure led to underestimation of the relationship of COPD with ETS, errors may not be random. Twenty-three of the 28 studies considered were of case-control or cross-sectional design, where recall bias may exist if those with COPD tend to overestimate their ETS exposure compared to those without COPD. Exposure was generally not validated by biochemical markers or air measurements taken at home.

Limited evidence for some sources of ETS
----------------------------------------

Only 15 studies (4, 5, 11, 12, 15--19, 21--23, 25--27) provided data on ETS exposure from sources other than the home. Five (4, 12, 17, 18, 27) presented results only for a combined household and workplace exposure index, with a further five (11, 15, 19, 21, 25) only presenting results for total exposure irrespective of location, results used in our analyses as the nearest equivalent which was available to smoking by the spouse or household member. While there are far less available data on risk of COPD from ETS exposure specifically in the workplace or in childhood than on smoking in the home, the available data show no clear relationship of risk with these less studied exposure indices.

Comparison with other recently published reviews
------------------------------------------------

A review in 2007 ^[@ref-73]^ considered that "ETS exposure may be an important cause of COPD". However, this conclusion was based on only six studies, one examining absolute risk of COPD in relation to changes in tobacco consumption, and one comparing lung function of employees in bars and restaurants before and after a smoking ban. Also it seemed that at least some of the others considered were not restricted to never smokers.

A review in 2010 ^[@ref-60]^ meta-analysed results from 12 studies and gave an overall estimate of 1.56 (1.40-1.74), somewhat higher than our estimate. Not all of the studies included were of COPD, some being based on chronic bronchitis symptoms. Also, some studies were based on current non-smokers rather than on lifelong never smokers.

In 2013, Bentayeb *et al.* ^[@ref-61]^ reviewed evidence on indoor air pollution and respiratory health in those aged over 65 years. After considering 33 papers (only one ^[@ref-16]^ presenting relevant results on ETS and COPD risk in non-smokers), they reported that the most consistent relationship found was between ETS exposure and COPD risk. However, the findings did not allow causal inference due to heterogeneity of the studies considered, measurement errors in exposure assessment, variable outcome definition, and lack of information on lifetime exposure to air pollution. The authors concluded that more investigations are needed to understand the relationship of indoor air pollution to respiratory health in the elderly.

A review in 2014 ^[@ref-74]^ reached similar conclusions, the authors stating that "second-hand exposure to tobacco smoke has also been shown to be associated with the risk of COPD, although more robust evidence needs to be generated". These conclusions were derived from only eight studies, some concerned with respiratory symptoms rather than COPD. Also, one study did not restrict any analyses to never smokers.

A review in 2015 ^[@ref-62]^ included only five studies in the meta-analyses. The estimated risk of COPD in ETS-exposed participants was higher than we estimated, being 1.66 (1.38-2.00) for both sexes combined, 1.50 (0.96-2.28) for males and 2.17 (1.48-3.18) for females. However, these estimates were based on, respectively, three, one and one estimates, the authors examining three further studies but not including them in their meta-analysis due to low study quality. However, two of the studies they did include were not based on lifelong never smokers. Many other studies that might have been included were not. The authors noted that "the few existing studies on second-hand smoke exposure and COPD differ considerably, although the results indicate a positive association" and that "further research is needed, to provide more adequate primary studies which account for confounding and other biases".

A review in 2016 ^[@ref-63]^ of "the effects of smoking on respiratory health" also considered effects of ETS exposure. However, only three studies were cited, two not satisfying our inclusion criteria. Noting the variability in the results, the authors only pointed to the need for additional studies.

Generally these reviews point to an association between ETS exposure and risk of COPD without concluding that a causal relationship has clearly been established. The present review, which includes far more studies, confirms the association and provides evidence that is strongly suggestive of a true effect. While this suggestion is not inconsistent with the view of the Global Burden of Disease Study 2017 ^[@ref-75]^ that second-hand smoke is a risk factor for COPD, limitations of the evidence, discussed above, precludes a more definitive conclusion.

Another relevant publication
----------------------------

In response to a comment from a reviewer (Dr Maio), we updated our searches by a further two years. While this identified an additional 99 publications, only one ^[@ref-76]^ satisfied our inclusion criteria. That paper reported age and sex adjusted hazard ratio estimates by level of ETS exposure, which, when combined, gave an exposed/unexposed estimate of 2.25 (95% CI 1.05-4.82). Including this estimate, based on only 33 COPD cases, had little effect on the meta-analysis results shown in [Table 4](#T4){ref-type="table"}. Thus, the overall random-effects estimate of 1.20 (95% CI 1.08-1.34) for all COPD was changed only to 1.22 (1.09-1.36), while that for Asia was changed only from 1.34 (1.08-1.67) to 1.38 (1.11-1.72).

Conclusion
==========

Taken in conjunction with the strong association of smoking with COPD, the significant relationship seen for the main index of ETS exposure, and the evidence of a dose-response relationship is highly suggestive that ETS also increases risk of COPD. However, the absence of well-designed and fully reported large studies, and the limitations noted above make it difficult to obtain an accurate estimate of the true magnitude of any possible effect. More definitive studies are required to reach a firmer conclusion.

Data availability
=================

Underlying data
---------------

There were no underlying data associated with this article

Extended data
-------------

**Supplementary file 1:** Rejected studies: In preparing the tables and figures in this document, certain papers that might be thought to provide relevant data have not been referred to. For each of these papers, this appendix notes the authors, date of publication and country and the reasons for not referring to them. <https://doi.org/10.17605/OSF.IO/8APGK> ^[@ref-77]^

**Supplementary file 2:** PRISMA checklist

<https://doi.org/10.17605/OSF.IO/8APGK> ^[@ref-77]^

**Supplementary file 3:** Forest plots in Excel

<https://doi.org/10.17605/OSF.IO/8APGK> ^[@ref-77]^
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I agree with the authors that it is difficult to define a causal relationship basing on the published evidences; but, on the other side, I think that the possible relationship between ETS and COPD should be better highlighted. The 2017 Global Burden of Disease study clearly reported that second-hand smoke is a risk factor for COPD deaths and DALYs.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Lee

Peter

P.N.Lee Statistics and Computing Ltd, UK

**Competing interests:**As previously described.
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I thank the reviewer for the comments.

As regards the comment about numbers of aspects and subsets, we have left the paper as it is. As a reader our strong preference is to have all the material to be considered in one place, without having to go backwards and forwards between the main paper and supplementary files. Readers can always skip reading information they are not interested in if they wish to.

We have however made a number of changes to the main messages put over. As shown in the red-lining these appear at the end of the abstract, near the end of the discussion section, and in the conclusions section. We now make it clear that the overall association with the main ETS exposure index, coupled with the dose-response evidence, and the evidence on smoking and COPD, provides strong evidence of a possible causal relationship, and note that this is consistent with the Global Burden of Disease 2017 statement that ETS is a risk factor. However we make it clear that one cannot go further based on the evidence - one cannot definitively conclude that ETS causes COPD - still less get very accurate estimation of its possible effect.

I hope that these alterations are sufficient to remove the reviewer\'s reservations.
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Version 1

The review is interesting, because it highlights methodological issues and gaps in surveys assessing the impact of environmental tobacco smoke on COPD incidence. These gaps and inconsistencies in surveys, lead to inadequacy on assessing the impact, and showing non-confirmative results (OR, RR, etc) on the association between ETS exposure and COPD.

I recommend it for indexing with minor changes.

However, the article should address three additional paragraphs or remark on: Public health message of awareness, it should address that, even if non association is found between ETS and COPD, it is still that ETS kills 90,0000 people per year and it is a global public health issue. Haahtela et al. Helsinki by nature. The nature step for respiratory health,Clinical and Transitional Allergy ^[@rep-ref-55818-1]^.Should mention water pipe because it is wide spreading: Yousser Mohammad, Rafea Shaaban, Bassam Abou Al-Zahab, Nikolai Khaltaev, Jean Bousquet, Basim Dubaybo. Impact of active and passive smoking as risk factors for asthma and COPD in women presenting to primary care in Syria: first report by the WHO-GARD survey group ^[@rep-ref-55818-2]^.  **WHO**Advisory note 2015: waterpipe tobacco smoking: health effects, research needs and recommended actions by regulators -- 2nd ed. World Health Organization. II.WHO Study Group on Tobacco Product Regulation.  ISBN 978 92 4 150846 9 (NLM classification: QV 137) ^[@rep-ref-55818-3]^.Should discuss the difference in the quality of ETS Not only nicotine but how the smoke is modified in the air and becoming may be more harmful to small airways: Lower ignition temperatureParticles become smallerHigher proportion of CO, VOC Ref found in the article: Mohammad Y. Passive smoking interference with wheezing and asthma Short Review of current knowledge ^[@rep-ref-55818-4]^.

Wirth et al. Respiratory diseases related to passive smoking ^[@rep-ref-55818-5]^. 

Beside that, in one study ^[@rep-ref-55818-6]^ the duration of exposure is 2 weeks, maybe we should omit it.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Lee

Peter

P.N.Lee Statistics and Computing Ltd, UK

**Competing interests:**See the statement in the paper
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**Reply to Yousser Mohammad**

Dr Mohammad suggests that I should cite a statement by WHO that ETS is responsible for about 900,000 deaths per year from all causes combined. We would rather not do this for two reasons. First, the paper is specifically about ETS and COPD, so does not need to stray into the relationship between ETS and other causes of death. Secondly, estimation of the effect of ETS on overall mortality is extremely complex and citation of a single estimate is questionable. We have in fact published widely on the evidence relating ETS to other diseases, such as lung cancer (Lee *et al*., 2016a; Lee *et al*., 2002), other cancers (Lee, 2002; Lee and Hamling, 2006; Lee and Hamling, 2016; Lee *et al*., 2016b), stroke (Lee and Forey, 2006; Lee *et al*., 2017b), heart disease (Lee *et al*., 2017a), and asthma (Lee and Forey, 2007), and find little evidence of an effect as large as WHO claims. For lung cancer, for example, we concluded (Lee *et al*., 2017b) that any causal relationship is not convincingly demonstrated, as most, if not all, of the relationship with ETS can be explained by confounding adjustment and misclassification correction.

Dr Mohammad also suggests that I mention waterpipes. We would prefer not to do this as the paper is about ETS exposure from conventional cigarettes and as we have not formally reviewed the evidence relating to waterpipes. We have made it clearer in the introduction that the paper concerns ETS from cigarettes.

He also suggests that we should discuss differences in the quality of ETS. We assume that he is pointing out that ETS from various products may not have the same composition or effects as from conventional cigarettes. But we are not concerned with ETS from products other than cigarettes.

He suggests that we refer to evidence relating ETS to wheezing and asthma. While the paper he cites does not actually mention COPD, we do now include a statement in the text at the end of paragraph 2 of the discussion.
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Version 1

The review could be of interest but some some major revisions are needed.

In particular, it would be important to update the papers selected for the revision because many other scientific evidences were published after June 2016.

Moreover, too many aspects and subsets are taken into account; they did not add information and they make the paper hard to read and the message not clear.

As regards to the subsets chosen for the meta-analysis, it would be important to take into account the publication period before and after the smoking ban, because it determined a variation in the exposure of the people to passive smoke and the related effects.

In the discussion, section \"publication bias\", it was reported that \" One must note, though, that various large longitudinal studies, e.g. 66--69, reported results relating ETS to smokingrelated diseases such as lung cancer or heart disease, but did not do so for COPD. If any relationship had been seen, these studies might well have been reported.\".

The reviewer thinks that this sentence is too strict and not supported by evidences.

Overall the discussion seems to set up versus a negative approach against the results of the other published reviews; on the other side, it did not discuss the results regarding the negative effect of exposure to ETS found using meta-analyses. The reviewer thinks that it is not to overlook the results about the dose-response evidence or the findings of the whole sample meta-analysis (OR 1.20) etc\...   

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Lee

Peter

P.N.Lee Statistics and Computing Ltd, UK

**Competing interests:**Our competing interests have already been described in the paper itself
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Dear Dr Maio,

I thank you for your comments which I respond to below on behalf of my co-authors.  The text of the paper has not yet been altered as the editorial team advise that I wait for the additional referee reports before doing so.

[Updating selected papers]{.ul}  You say that \"many other scientific evidences were published after June 2016.  However, we have updated our searches to cover more recent papers, and only found one paper which satisfied the inclusion criteria. This was a report by Ukawa et al in 2017 (International Journal of Public Health, vol 62, pp 489-494) which presented results for at home passive smoking exposure from the Japan Collaborative cohort study, based only on 33 cases. Rather than updating the whole range of analysis results, we intend simply to refer to this additional study, and the effect it had on the overall effect estimate, in a comment at the end of the discussion section.  If you think there are other important papers we have missed please let us know what they are.

[Too many aspects and subsets are taken into account]{.ul}  We have published a number of previous reviews of the relationship of passive smoking to other diseases, and this style has never before been criticized.  In our view it is important to fully describe how the association of interest varies by the source of exposure and by study characteristics, and also by the definition of disease.  One cannot get a good insight without these details.

[Taking into account the publication period before and after the smoking ban]{.ul}  You say \"the smoking ban\" but there are many smoking bans, different in type and different in timing. In the US for example different states, and different locations within states, brought in bans at different times. When one also considers the long latent period of COPD, with deaths post-ban perhaps due to exposures pre-ban, and the fact that in some studies some COPD cases occur pre-ban and some post-ban, we did not consider it useful to attempt the required analysis.

[Publication bias]{.ul}   We made the point (also made in other passive smoking reviews) that some large cohort studies are known to have published positive relationships relating passive smoking to other diseases when they did not publish results relating passive smoking to COPD.  Surely it is quite likely that they did not find a.positive relationship for COPD?   In my view large cohort studies ought to publish passive smoking results for all diseases with sufficient cases, but often they do not.  Our comment is supported by the evidence as to what has and has not been published - though this does not prove that all such studies found no positive association with COPD, the likelihood is there.  The argument is similar to the general one for publication bias.  We don\'t generally have evidence that  papers showing no association are less likely to be submitted or accepted than papers finding an association, but it is highly plausible.

[Negative approach against other reviews]{.ul}   We state the reasons why these other reviews are limited.

[Overlooking evidence suggesting an association, such as the dose-response results and the overall meta-analysis results]{.ul}   In paragraph 2 of the discussion we refer to the overall meta-analysis results and the dose-response results, and then go on to discuss why these results are only suggestive of a causal relationship.  The overall association of 1.20 with passive smoking at home, though highly statistically significant, is quite small in magnitude, and it is certainly possible that it may be explicable in terms of bias.  In our review of passive smoking and lung cancer (World Journal of Meta-Analysis, 2017, 4, 10-43) we were able to demonstrate quite clearly that a similar sized association could plausibly be explained by a combination of uncontrolled confounding and misclassification of smoking status.  Though the data for COPD are not extensive enough to readily allow such adjustments, we would be extremely nervous in saying that the association is more than suggestive of a causal relationship.  Nevertheless, we will look again at the wording we have used and try to make our argument clearer.

[Conclusions drawn not adequately supported by the results presented]{.ul}   This really relates to the previous point.  We believe our conclusions are supported by the results.

We would be happy to hear your reactions to our replies.

Yours sincerely

Peter Lee (and co-authors)

[^1]: **Competing interests:**PNL, Director of P.N. Lee Statistics and Computing Ltd., is an independent consultant in statistics and an advisor in epidemiology to various tobacco companies, including the sponsors of this study. KJC is an employee of, and AJT a consultant to, P.N. Lee Statistics and Computing Ltd. BAF and JSH were also employees when the work was conducted.
